Quest Diagnostics stock holds above $244 as earnings and guidance support outlook
Published on 08/22/2026 at 12:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quest Diagnostics Inc. (ISIN US74834L1008) stock is trading at $244.43 as of August 22, 2026, reflecting a gain of 1.30% in the latest session while investors weigh strong recent earnings and full-year 2026 guidance for this major diagnostic testing provider. Recent market data show the shares opened at $240.33, reached a high of $244.70 and a low of $239.43, with 701,437 shares changing hands, highlighting solid liquidity in the New York Stock Exchange listing.
Per the latest quarterly figures released for the period ended in late July 2026, Quest Diagnostics reported earnings per share of $3.12, beating consensus estimates of $2.82 by $0.30 and underscoring operational leverage in its testing network. The same earnings overview indicates revenue of $3.04 billion for the quarter versus a consensus expectation of $2.97 billion, representing 10.2% year-over-year growth compared with the prior-year quarter revenue level, which reinforces the demand backdrop for diagnostic services.
Alongside the beat on earnings and revenue, Quest Diagnostics posted a net margin of 9.18% and a return on equity of 16.01% for that latest reported quarter, numbers that position the company as a profitable and capital-efficient player within healthcare diagnostics. The year-over-year comparison reveals that in the same quarter a year earlier, the company earned $2.62 per share, so the current $3.12 EPS figure reflects a notable step-up in profitability that may appeal to investors seeking stable earnings growth rather than aggressive cyclicality.
Earnings guidance and consensus expectations
Looking beyond the single quarter, Quest Diagnostics has issued guidance for fiscal 2026, targeting full-year earnings per share in the range of $11.05 to $11.25, which frames management’s view of sustainable profitability given current volume trends and reimbursement dynamics. The same guidance commentary notes that analyst models currently converge at an EPS expectation of $11.15 for the year, placing the consensus almost precisely at the midpoint of management’s range and signaling a relatively tight alignment between internal and external expectations.
Recent earnings analysis also points to a consensus revenue forecast of $12.01 billion for 2026, representing 8.9% growth versus the prior-year revenue base, which would mark a continuation of the double-digit quarterly growth rate observed in the latest report rather than a one-off spike. The consensus overview illustrates that projected EPS growth of 13.2% from the prior year to $11.15 aligns with the revenue growth expectations, suggesting that pricing, mix and cost control are all contributing to margin preservation even as volumes expand.
For investors, the combination of an earnings beat, rising consensus forecasts and clear guidance can help reduce uncertainty around near-term cash flows and dividend coverage. With the payout ratio reported at 36.52%, Quest Diagnostics maintains significant retained earnings for reinvestment or balance-sheet flexibility, which is relevant in a healthcare environment where reimbursement changes and regulatory developments can affect long-term profitability.
Dividend profile and valuation context
Income-focused investors may also consider the dividend profile that accompanies Quest Diagnostics stock. The company recently announced a quarterly dividend of $0.86 per share, translating into an annualized dividend of $3.44 and a dividend yield of 1.4% at prevailing share prices, which adds a modest income component to the total-return proposition. Dividend data in the same coverage highlight that the current payout ratio leaves room for future dividend growth if earnings track toward or above the upper end of the 2026 guidance range, although actual increases would depend on board decisions and broader capital allocation priorities.
Recent market data show the shares trading at $244.43 with a consensus price target of $235.31, implying that the current market price sits modestly above the aggregated analyst target. The same consensus snapshot characterizes the rating stance as a Moderate Buy, indicating that while many analysts are positive on the stock, they also regard the valuation as relatively full when compared with their target estimates, which could temper expectations for outsized short-term gains absent new catalysts.
Rating actions also reflect this constructive but measured view. A recent research note raised the shares from a buy rating tier labeled b+ to a higher tier labeled a-, signaling an incremental upgrade based on perceived improvements in earnings quality or risk profile. Combined with the guidance and consensus picture, this ratings context underscores that Quest Diagnostics is seen as a steady compounder in healthcare rather than a speculative growth play, which often appeals to investors looking for defensive exposure with visible cash returns.
Core diagnostic services and growth drivers
Quest Diagnostics builds its financial performance on a broad portfolio of diagnostic testing services, including routine blood work, advanced esoteric tests and specialty diagnostics that support physicians, hospitals and health plans. These services generate recurring demand because they sit at the center of preventive care, chronic disease management and clinical decision-making, which helps stabilize volumes even when macroeconomic conditions are volatile.
The 10.2% year-over-year revenue increase in the latest quarter suggests that both volume and possibly test complexity have moved higher compared with the prior-year period. As more physicians adopt personalized medicine approaches and payers encourage early detection of conditions such as diabetes, cardiovascular disease and cancer, Quest Diagnostics can capture incremental test orders in higher-value categories, supporting revenue growth that runs ahead of general population growth.
Digital ordering platforms, data analytics tools and integrated lab networks are also relevant growth drivers. By streamlining test ordering and result delivery for clinicians and patients, Quest Diagnostics can reduce friction in the diagnostic journey, potentially increasing physician loyalty and enhancing its competitive position against regional labs and hospital-based testing units. Operational efficiency gains from automation and centralized processing facilities contribute to the margin outcomes reflected in the latest EPS beat and net margin metrics.
DGX shares and recent trading behavior
From a trading standpoint, Quest Diagnostics shares have shown steady investor interest in the latest session. The share price of $244.43 as of August 22, 2026, with a 1.30% increase in that session, signals moderate positive momentum rather than a sharp technical breakout. The quote overview details an intraday range between $239.43 and $244.70, with 701,437 shares traded, which indicates active but not extreme turnover relative to typical daily volume for a mid-large cap healthcare stock.
Investors may interpret this trading pattern as the market consolidating gains following the earnings beat while digesting the guidance and consensus updates. Because the current share price stands above the consensus target of $235.31, some market participants might expect the shares to trade sideways or within a defined range unless new data, such as updated guidance, acquisitions or regulatory developments, alter the earnings trajectory meaningfully.
For long-term holders, the key variables remain the pace of revenue growth, the sustainability of double-digit EPS increases and the company’s ability to maintain margins in the face of reimbursement pressure and competition. The recent quarter’s performance, with EPS rising from $2.62 a year earlier to $3.12 now and revenue up 10.2%, offers tangible evidence that Quest Diagnostics is currently managing these challenges effectively.
Representative service: comprehensive diagnostic testing
A representative product offering that illustrates the company’s role in healthcare is its broad menu of comprehensive diagnostic testing services, typically accessed through physicians and health systems across the United States. These services encompass standard panels such as complete blood counts and metabolic profiles, as well as more specialized tests for infectious diseases, genetic conditions and oncology markers, all of which help clinicians diagnose, monitor and treat patients more effectively.
Because these tests often form part of standard-of-care protocols and chronic disease management pathways, they generate recurring demand and contribute to the relatively stable revenue base reflected in the company’s quarterly results and full-year guidance. For patients and providers, the ability to access a wide range of tests through a single national network simplifies logistics and can reduce turnaround times, which in turn supports clinical decision-making and overall care quality.
Quest Diagnostics stock at current levels
Quest Diagnostics stock currently trades at $244.43 as of August 22, 2026, on the New York Stock Exchange, with the latest session showing a gain of 1.30% alongside an intraday high of $244.70 and low of $239.43. Against the backdrop of fiscal 2026 EPS guidance in the $11.05 to $11.25 range, consensus EPS of $11.15 and a dividend yield of 1.4%, the shares present a blend of earnings growth and income that positions them as a defensive healthcare holding rather than a short-term speculative trade.
Fact box
Company: Quest Diagnostics Inc.
ISIN: US74834L1008
Ticker: DGX
Exchange: New York Stock Exchange
Price (as of August 22, 2026, 1:29 a.m. ET): $244.43 USD
Market cap: value based on current share price and outstanding shares, not specified in the cited sources
Sector / Industry: Health care / Diagnostic testing and medical laboratories
Index membership: S&P 500
